NSNima Sharifi

Nima Sharifi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nima Sharifi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • William L. Farrar

    Cancer Stem Cell Section, Laboratory of Cancer Prevention, National Cancer Institute at Frederick, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland

    3 shared publications
  • William D. Figg

    National Cancer Institute, Medical Oncology Branch, Bethesda, Maryland, USA

    2 shared publications
  • Amanda Jones

    Division of Pharmaceutics, College of Pharmacy, Ohio State University, Columbus, Ohio

    1 shared publication
  • Brian T. Kawasaki

    Cancer Stem Cell Section, Laboratory of Cancer Prevention, National Cancer Institute at Frederick, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland

    1 shared publication
  • Charles T. Kane

    Starks Associates, Inc., Buffalo, New York; and

    1 shared publication
  • Elaine M. Hurt

    Cancer Stem Cell Section, Laboratory of Cancer Prevention, National Cancer Institute at Frederick, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland

    1 shared publication

Latest Publications

  • Open Access

    Secondary hormonal therapy for prostate cancer: what lies on the horizon?

    by Nima Sharifi, William L. Dahut, William D. Figg

    Androgen deprivation therapy with medical or surgical castration is generally the first‐line treatment against advanced prostate cancer. Almost invariably, metastatic prostate cancer overcomes testosterone depletion and grows, despite castrate levels of testosterone. Despite advances in cytotoxic chemotherapy, secondary hormonal therapies are often used after the development of castrate‐resistant prostate cancer. Secondary hormonal therapies either lower the androgen levels further or directly antagonize the androgen receptor in prostate cancer cells. We discuss novel secondary hormonal agents that are under development, which work by either inhibiting androgen synthesis or directly targeting the androgen receptor.


  • Open Access

    Transforming growth factor-β receptor III downregulation in prostate cancer: is inhibin B a tumor suppressor in prostate?

    by Nima Sharifi, Robert J Lechleider, William L Farrar

    The transforming growth factor-β (TGF-β) pathway plays dual roles in cancer, inhibiting epithelial cell growth under normal physiologic conditions, but promoting invasion and metastasis once growth inhibitory responses are lost. Two recent papers show that TGF-β receptor III is the most common TGF-β pathway component downregulated in prostate cancer. Here, we discuss the implications of these findings and what it may mean about the biology of this disease.


  • Open Access

    Androgen receptor modulation: lessons learned from beyond the prostate.

    by Nima Sharifi, William D. Figg

    Androgen receptor (AR) is an important transcription factor in prostatic diseases, such as prostate cancer and benign prostatic hyperplasia (BPH). AR regulates the growth and survival of both benign and cancerous prostate epithelial cells. Therefore, modulation of AR function is an important means of treating prostatic diseases. Modern pharmacotherapy for these diseases includes, for example, medical castration and AR antagonists for prostate cancer and 5-alpha-reductase inhibitors for BPH. However, these treatments have limitations and are illustrated by AR reactivation after medical castration for prostate cancer, commonly termed castrate-resistant prostate cancer. A novel method of AR modulation has been demonstrated in spinal and bulbar muscular atrophy, a disease defined by a polyglutamine repeat expansion which leads to gain-of-function changes in AR and neuromuscular pathology. Here, we examine recent findings from the description of a compound that degrades AR and induces dissociation of AR from an AR coactivator. The biochemistry of this compound may have implications for prostate cancer.


  • Open Access

    A bifunctional colchicinoid that binds to the androgen receptor

    by Nima Sharifi, Ernest Hamel, Markus A. Lill, Prabhakar Risbood, Charles T. Kane, Tafazzal Hossain, Amanda Jones, James T. Dalton, William L. Farrar

    Castrate-resistant prostate cancer (CRPC) continues to be dependent on the androgen receptor (AR) for disease progression. We have synthesized and evaluated a novel compound that is a conjugate of colchicine and an AR antagonist (cyanonilutamide) designed to inhibit AR function in CRPC. A problem in multifunctional AR-binding compounds is steric hindrance of binding to the embedded hydrophobic AR ligand-binding pocket. Despite the bulky side chain projecting off of the AR-binding moiety, this novel conjugate of colchicine and cyanonilutamide binds to AR with a Ki of 449 nmol/L. Structural modeling of this compound in the AR ligand-binding domain using a combination of rational docking, molecular dynamics, and steered molecular dynamics simulations reveals a basis for how this compound, which has a rigid alkyne linker, is able to bind to AR. Surprisingly, we found that this compound also binds to tubulin and inhibits tubulin function to a greater degree than colchicine itself. The tubulin-inhibiting activity of this compound increases cytoplasmic AR levels in prostate cancer cells. Finally, we found that this compound has greater toxicity against androgen-independent prostate cancer cells than the combination of colchicine and nilutamide. Together, these data point to several ways of inhibiting AR function in CRPC. [Mol Cancer Ther 2007;6(8):2328–36]


  • TGFBR3 loss and consequences in prostate cancer

    by Nima Sharifi, Elaine M. Hurt, Brian T. Kawasaki, William L. Farrar

    Background: Resistance to transforming growth factor‐beta (TGF‐β) is important in tumorigenesis. TGF‐β resistance mechanisms in prostate cancer are not well understood.Methods: We have conducted a systematic analysis of TGF‐β pathway components with a meta‐analysis of seven microarray studies using Oncomine and evaluated the results of TGFBR3 expression in prostate cell lines. Furthermore, we knocked down TGFBR3 in prostate epithelial cells and analyzed the consequences of TGFBR3 knockdown.Results: We found that TGFBR3 is the TGF‐β component most commonly downregulated among localized human prostate cancer studies. TGFBR3 knockdown led to focus formation and enhanced expression of CD133, a marker found on prostate cancer stem cells. DNA microarray analysis of TGFBR3 knockdown cells identified 101 genes regulated by TGFBR3. Seven of these genes show a corresponding decrease in clinical prostate cancer specimens, which include genes involved in prostate mass and vasculature.Conclusions: TGFBR3 downregulation is an important step in prostate tumorigenesis. Prostate 67:301–311, 2007.


  • Androgen Receptor as a Therapeutic Target for Androgen Independent Prostate Cancer

    by Nima Sharifi, William L. Farrar

    Prostate cancer is the leading cause of nonskin malignancy and the second leading cause of cancer death in men. Androgen deprivation therapy is the first-line of systemic therapy against advanced prostate cancer. All advanced prostate cancers eventually grow despite castrate levels of testosterone. We review the evidence that androgen independent prostate cancer continues to require androgen receptor activity for growth, the mechanisms of androgen receptor activation in the castrate setting, and possible points of intervention for novel therapies targeting the androgen receptor and prostate cancer.